Cite
HARVARD Citation
Cohen, S. et al. (2019). Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext). Expert opinion on biological therapy. pp. 1097-1105. [Online].